Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha H A Hussain

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Urology|January 30, 2004
The patient with hormone-refractory prostate cancer: determining who, when, and how to treatElizabeth C Kent, Maha H A Hussain
Cancer|April 3, 2015
Addressing apoptosis to tumor zip codesZachery R Reichert, Maha H A Hussain
Current Opinion in Urology|February 14, 2003
The rationale for adjuvant chemotherapy for high-risk prostate cancerElizabeth C Kent, Maha H A Hussain
Future Oncology (London, England)|March 25, 2025
Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summaryFred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Journal of the National Cancer Institute|February 13, 2009
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trialMichael E Ray, Kyounghwa Bae, Maha H A Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology GroupMichael K Gibson, Yi Li, Barbara Murphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trialThomas W Flaig, Catherine M Tangen, Maha H A Hussain, et al.
Prostate Cancer and Prostatic Diseases|January 9, 2021
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusionsZachary R Chalmers, Michael C Burns, Ericka M Ebot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancerEthan M Basch, Mark R Somerfield, Tomasz M Beer, et al.
JAMA Oncology|March 31, 2017
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone InductionThomas W Flaig, Melissa Plets, Maha H A Hussain, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Urology|January 30, 2004
The patient with hormone-refractory prostate cancer: determining who, when, and how to treatElizabeth C Kent, Maha H A Hussain
Cancer|April 3, 2015
Addressing apoptosis to tumor zip codesZachery R Reichert, Maha H A Hussain
Current Opinion in Urology|February 14, 2003
The rationale for adjuvant chemotherapy for high-risk prostate cancerElizabeth C Kent, Maha H A Hussain
Future Oncology (London, England)|March 25, 2025
Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summaryFred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Journal of the National Cancer Institute|February 13, 2009
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trialMichael E Ray, Kyounghwa Bae, Maha H A Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology GroupMichael K Gibson, Yi Li, Barbara Murphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trialThomas W Flaig, Catherine M Tangen, Maha H A Hussain, et al.
Prostate Cancer and Prostatic Diseases|January 9, 2021
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusionsZachary R Chalmers, Michael C Burns, Ericka M Ebot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancerEthan M Basch, Mark R Somerfield, Tomasz M Beer, et al.
JAMA Oncology|March 31, 2017
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone InductionThomas W Flaig, Melissa Plets, Maha H A Hussain, et al.
Pageof 4